Article
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study.
Acta oncologica (Stockholm, Sweden) - 1 Jul 2020
Ree Anne Hansen, Nygaard Vigdis, Boye Kjetil, Heinrich Daniel, Dueland Svein, Bergheim Inger Riise, Johansen Christin, Beiske Klaus, Negård Anne, Lund-Iversen Marius, Nygaard Vegard, Hovig Eivind, Nakken Sigve, Nasser Salah, Julsrud Lars, Reisse Claudius H, Ruud Espen A, Kristensen Vessela N, Flørenes Vivi A, Geitvik Gry A, Lingjærde Ole Christian, Børresen-Dale Anne-Lise, Russnes Hege G, Mælandsmo Gunhild M, Flatmark Kjersti
Abstract excerpt
Background: In precision cancer medicine, the challenge is to prioritize DNA driver events, account for resistance markers, and procure sufficient information for treatment that maintains patient safety. The MetAction project, exploring how tumor molecular vulnerabilities predict therapy response, first established the required workflow for DNA sequencing and data interpretation (2014-2015). Here, we employed it...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.